Navigating the Institutional Review Board (IRB) process is a foundational aspect of conducting ethical and compliant research. For researchers familiar with expedited or exempt review processes, the idea of transitioning to a full board review may seem daunting or even unnecessary. However, there are specific instances where a study initially qualifying as expedited or exempt may require full board review due to unforeseen factors. Understanding these scenarios is critical to maintaining compliance and adapting your research strategy effectively.
This blog will explore the distinctions between exempt, expedited, and full board reviews, discuss when and why transitions to a full board review occur, and provide actionable insights to help researchers succeed in their studies while staying true to ethical and regulatory standards.
What Are Expedited and Exempt Reviews?
Before we examine the circumstances that necessitate a full board review, it’s essential to understand the criteria and scope of expedited and exempt reviews.
Exempt Studies
An exempt study involves research activities that present minimal risk to participants and fall within specific categories outlined by regulations like the Common Rule (45 CFR 46.104). These categories often include:
- Educational settings: Studies conducted in established or commonly accepted educational practices.
- Surveys and interviews: Provided they don’t involve sensitive information or identifiable private data.
- Publicly available data: Studies involving information that is already available to the public and does not pose a privacy risk to individuals.
While termed “exempt,” these studies still require IRB oversight to confirm that they meet the appropriate criteria for this designation.
Expedited Studies
Expedited studies also involve minimal risk to participants but require more scrutiny than exempt studies. Research that qualifies for expedited review must fall under federally defined categories (45 CFR 46.110) such as:
- Collection of biological samples: Like blood via non-invasive means.
- Prospective data collection: Using materials already collected for non-research purposes.
- Studies involving specific clinical data: Including non-invasive procedures approved for clinical practice.
Expedited reviews are conducted by a subset of IRB members rather than a full board, making the process quicker while ensuring compliance.
When Might a Study Transition to Full Board Review?
Although studies may qualify as exempt or expedited initially, certain developments either during the IRB application process or once research has started post-IRB approval can necessitate a full board review. Here are the most common scenarios:
1. Introduction of More Than Minimal Risk
Changes to a study’s design that amplify risk levels to participants can push it beyond the boundaries of an expedited or exempt review. For instance:
- Adding invasive procedures: Such as surgeries or biopsies.
- Introducing sensitive questions: Surveys that now inquire about illegal activities, sexual behavior, or mental health could increase psychological risks.
- Data breach concerns: Altering your study to include identifiable, private data could present risks related to confidentiality.
2. Vulnerable Populations
If the study scope expands to include vulnerable populations, such as children, prisoners, or individuals with cognitive disabilities, it may require a full board review. These groups are afforded extra protections under guidelines like Subparts B, C, and D of 45 CFR 46, making full board oversight essential in some cases.
3. Significant Protocol Changes
Substantive changes to an approved protocol, such as revisions in recruitment strategies or broadening the criteria for participation, can trigger the need for a full board review. Examples include:
- Recruiting participants outside the initial demographic: Shifting from adults to adolescents.
- Changing methods of data collection: Moving from anonymous surveys to in-depth interviews.
4. Adverse Events or Unanticipated Problems
If adverse events occur during the study or unanticipated risks emerge, the IRB may escalate the review to a full board to reassess the risks and ensure participant safety. Examples include:
- Unexpected side effects: Not previously identified in the initial proposal.
- Breaches of confidentiality: That could harm participants.
5. Ethical or Legal Concerns
Questions regarding the ethical implications of the research or compliance with regulatory frameworks might prompt a full board review. For example:
- Ethical dilemmas around consent forms.
- Legal issues with participant privacy laws, especially in studies involving international data collection.
Recommendations for Navigating These Situations
To minimize disruptions and maintain compliance, researchers should adopt these best practices:
- Anticipate Risks Early: Before submitting for IRB review, consider potential risk factors that could escalate the study’s review status.
- Monitor and Report Changes Promptly: Maintain open communication with your IRB regarding potential protocol changes or emerging risks.
- Engage Your IRB: Leverage the expertise of your IRB members to ensure that you remain ahead of regulatory requirements.
- Document Everything: Keep detailed records of your decisions and protocols, which can help justify changes during reviews.
Additionally, researchers should stay updated on the latest in regulatory guidelines to ensure compliance with evolving standards.
Staying Ahead in Research Compliance
Understanding the nuances of when a study transitions from exempt or expedited to a full board review is crucial for protecting the integrity of your research and the safety of your participants. Committing to best practices in anticipation and communication will help you avoid delays while fostering a strong relationship with your IRB. Ultimately, ethical and compliant research paves the way for trust, credibility, and impactful outcomes in the larger academic and scientific community.